Wegovy pill scripts hit 26,000 as earnings week approaches
Copenhagen, Jan 31, 2026, 20:48 CET — The market has closed.
- Shares of Novo Nordisk Class B ended at 369.55 Danish kroner, slipping 0.23% following a nearly 8% drop over the past five sessions.
- Initial U.S. prescription figures have drawn attention to the company’s recently released Wegovy weight-loss drug.
- Upcoming catalyst: Feb. 4 quarterly results and 2026 outlook, spotlight on oral Wegovy adoption and competitive pressures in China.
Novo Nordisk’s Class B shares on the Copenhagen exchange slipped 0.23% to 369.55 Danish kroner Friday, marking roughly a 7.9% drop over the past five sessions. Investors now face a short weekend to process an expanding roster of catalysts. (MarketScreener)
The stock’s…
